肝细胞癌综合治疗进展

傅毅振; 徐立

doi:10.3969/j.issn.1001-5256.2020.10.004

肝细胞癌综合治疗进展

DOI: 10.3969/j.issn.1001-5256.2020.10.004

傅毅振,
徐立

中山大学肿瘤防治中心肝脏外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1112
- HTML全文浏览量: 33
- PDF下载量: 217
- 被引次数: 0
出版历程
- 收稿日期: 2020-07-10
- 出版日期: 2020-10-20

Advances in multimodality therapy for hepatocellular carcinoma

Fu YiZhen,
Xu Li

Department of Liver Surgery,Sun Yat-sen University Cancer Center

摘要

摘要: 原发性肝癌是全球范围内最常见的恶性肿瘤之一,其中肝细胞癌占据了约90%的病例。包括手术、消融、介入、靶向和免疫治疗在内的多学科综合治疗是肝癌治疗的有效策略。近年来,肝癌的综合治疗取得了令人惊喜的进展,特别是中晚期肝癌的联合治疗以及药物研发的进步,使肝癌患者的整体预后得到大幅改善,靶向药物和免疫治疗的进步更有望改变肝癌的综合治疗模式。现就局部治疗和系统治疗两个大方向系统性地对近期肝癌综合治疗的进展进行论述。
- 癌,肝细胞 /
- 治疗学
Abstract: Primary liver cancer is one of the most common malignances worldwide,among which hepatocellular carcinoma( HCC) accounts for about 90% of all cases. Multidisciplinary multimodality therapy involving surgery,ablation,interventional treatment,targeted therapy,and immunotherapy is an effective strategy for the treatment of liver cancer. In recent years,great achievements have been made in multimodality therapy for liver cancer,especially the advances in combination therapy for advanced liver cancer and drug research and development,which improves the overall prognosis of liver cancer patients,and the improvement in targeted drug therapy and immunotherapy is expected to change the pattern of multimodality therapy for liver cancer. This article systematically reviews the recent advances in multimodality therapy for liver cancer from the aspects of local treatment and systemic therapy.
- carcinoma,hepatocellular /
- therapeutics

HTML全文

参考文献(28)

[1] WEI W,ZENG H,ZHENG R,et al. Cancer registration in China and its role in cancer prevention and control[J]. Lancet Oncol,2020,21(7):e342-e349.

[2] XIA Y,LI J,LIU G,et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma:A randomized clinical trial[J]. JAMA Oncol,2019.[Online ahead of print]

[3] CHAN A,ZHANG WY,CHOK K,et al. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma:A changing paradigm in modulation of future liver remnant before major hepatectomy[J]. Ann Surg,2019.[Online ahead of print]

[4] RAJYAGURU DJ,BORGERT AJ,SMITH AL,et al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients:Analysis of the national cancer database[J]. J Clin Oncol,2018,36(6):600-608.

[5] HARA K,TAKEDA A,TSURUGAI Y,et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation:A propensity score analysis[J]. Hepatology,2019,69(6):2533-2545.

[6] KIM N,CHENG J,JUNG I,et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma[J]. J Hepatol,2020,73(1):121-129.

[7] WEI XB,JIANG YB,ZHANG XP,et al. Neoadjuvant threedimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus:A randomized,open-label,multicenter controlled study[J]. J Clin Oncol,2019,37(24):2141-2151.

[8] KUDO M,UESHIMA K,IKEDA M,et al. Randomised,multicentre prospective trial of transarterial chemoembolisation(TACE)plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma:TACTICS trial[J]. Gut,2020,69(8):1492-1501.

[9] HE MK,LI QJ,ZOU RH,et al. Sorafenib plus hepatic arterial infusion of oxaliplatin,fluorouracil,and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion:A randomized clinical trial[J]. JAMA Oncol,2019,5(7):953-960.

[10] MAI Q,MO Z,SHI F,et al. Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol,2020,38(15_suppl):e16603.

[11] European Association for the Study of the Liver. EASL clinical practice guidelines:Management of hepatocellular carcinoma[J]. J Hepatol,2018,69(1):182-236.

[12] CHEN JH,LU L,WEN TF,et al. Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse(LANCE):Interim results from a muticenter prospective cohort study[J]. J Clin Oncol,2020,38(15_suppl):4580.

[13] BI F,QIN S,GU S,et al. Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma:An open-label,randomized,multicenter phase II/III trial[J]. J Clin Oncol,2020,38(15_suppl):4506.

[14] LI Q,QIN S,GU S,et al. Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma:A randomized,placebo-controlled,double-blind,phase III study[J]. J Clin Oncol,2020,38(15_suppl):4507.

[15] YAU T,PARK JW,FINN RS,et al. CheckMate 459:A randomized,multi-center phase III study of nivolumab(NIVO)vs sorafenib(SOR)as first-line(1L)treatment in patients(pts)with advanced hepatocellular carcinoma(a HCC)[J].Annals of Oncology,2019,30:874.

[16] FINN RS,RYOO BY,MERLE P,et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240:A randomized,double-blind,phase III trial[J]. J Clin Oncol,2019:JCO1901307.

[17] FINN RS,QIN S,IKEDA M,et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med,2020,382(20):1894-1905.

[18] ZHU AX,FINN RS,IKEDA M,et al. A phase Ib study of lenvatinib(LEN)plus pembrolizumab(PEMBRO)in unresectable hepatocellular carcinoma(u HCC)[J]. J Clin Oncol,2020,38(15_suppl):4519.

[19] KASEB AO,CAO HST,MOHAMED YI,et al. Final results of a randomized,open label,perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC[J]. J Clin Oncol,2020,38(15_suppl):4599.

[20] SUN HC,ZHU XD,HUANG C,et al. Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection[J]. J Clin Oncol,2020,38(15_suppl):e16690.

[21] TAI WMD,LOKE KSH,GOGNA A,et al. A phase II open-label,single-center,nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma:CA 209-678[J]. J Clin Oncol,2020,38(15_suppl):4590.

[22] BROWN CE,MACKALL CL. CAR T cell therapy:Inroads to response and resistance[J]. Nat Rev Immunol,2019,19(2):73-74.

[23] MAUDE SL,LAETSCH TW,BUECHNER J,et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J]. N Engl J Med,2018,378(5):439-448.

[24] NEELAPU SS,LOCKE FL,BARTLETT NL,et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma[J]. N Engl J Med,2017,377(26):2531-2544.

[25] BO MD,MATTIA ED,BABOCI L,et al. New insights into the pharmacological,immunological,and CAR-T-cell approaches in the treatment of hepatocellular carcinoma[J]. Drug Resist Updat,2020,51:100702.

[26] GAO H,LI K,TU H,et al. Development of T cells redirected to Glypican-3 for the treatment of hepatocellular carcinoma[J]. Clin Cancer Res,2014,20(24):6418-6428.

[27] CHOI J,KIM HJ,LEE J,et al. Risk of hepatocellular carcinoma in patients treated with Entecavir vs Tenofovir for chronic hepatitis B:A Korean Nationwide cohort study[J]. JAMA Oncol,2019,5(1):30-36.

[28] CHOI J,JO C,LIM YS. Tenofovir vs. Entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection[J]. Hepatology,2020.[Online ahead of print]

施引文献

资源附件(0)

访问统计